Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
clinical trials
5
×
life sciences
national blog main
5
×
national top stories
new york top stories
novartis
5
×
boston blog main
boston top stories
national
new york blog main
san francisco top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alder biopharmaceuticals
alnylam pharmaceuticals
biogen
bristol-myers squibb
cancer
cell therapy
deals
diagnostics
drug prices
What
drug
5
×
new
fda
approval
bio
brings
medicines
patients
roundup
acquire
advantages
agreed
amgen
approved
atrophy
bar
billion
biogen’s
biopharmaceutical
candidates
cash
cholesterol
class
companies
company
compound
convo
daily
deal
developed
earlier
evrysdi
expect
failures
friday
gamble
gets
green
head
home
Language
unset
Current search:
drug
×
biotech
×
novartis
×
" clinical trials "
×
" national blog main "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines